In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on CymaBay Therapeutics (CBAY), with a price target of $9.00. The company’s shares closed last Friday at $6.12, close to its 52-week high of $7.09.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 15.5% and a 48.6% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals.
Currently, the analyst consensus on CymaBay Therapeutics is a Strong Buy with an average price target of $12.63, representing a 105.7% upside. In a report issued on August 25, Citigroup also maintained a Buy rating on the stock with a $9.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.09 and a one-year low of $1.21. Currently, CymaBay Therapeutics has an average volume of 3.6M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
Read More on CBAY:
